Sort   by:  
 Page size 
MetabolomicsPRDM15 is a master regulator of metabolism essential to sustain B-cell lymphomagenesis
PRDM family members are sequence-specific transcriptional regulators involved in cell identity and fate determination and are often dysregulated in cancer. The PRDM15 gene is of particular interest, given its relatively low expression in adult tissues and its overexpression in follicular lymphomas (...
2025-06-16 | MTBLS1639 | MetaboLights
GenomicsQuantitative imaging of RAD51 expression as a marker of platinum resistance in Ovarian Cancer
Quantitative imaging of RAD51 expression as a marker of platinum resistance in Ovarian Cancer
PRJNA701239 | ENA
GenomicsPatterns of oncogene co-expression at single-cell resolution influence clinical outcome in Diffuse Large B-Cell Lymphoma.
Patterns of oncogene co-expression at single-cell resolution influence clinical outcome in Diffuse Large B-Cell Lymphoma.
PRJNA840875 | ENA
ProteomicsDataset12_DLBCL clinical sample 2 5h Gemcitabine ITDR
Freshly isolated PBMCs from a R/R DLBCL patient were treated with increasing gemcitabine concentrations (and vehicle control) for 5h, collected and subjected to CETSA heating, followed by cell lysis, isolation of soluble fraction and sample preparation for MS including digestion, desalting, TMT labe...
ORGANISM(S): Homo Sapiens (human) 
2025-06-12 | PXD054910 | JPOST Repository
ProteomicsDataset11_DLBCL clinical sample 1 5h Gemcitabine ITDR
Freshly isolated PBMCs from a R/R DLBCL patient were treated with increasing gemcitabine concentrations (and vehicle control) for 5h, collected and subjected to CETSA heating, followed by cell lysis, isolation of soluble fraction and sample preparation for MS including digestion, desalting, TMT labe...
ORGANISM(S): Homo Sapiens (human) 
2025-06-12 | PXD054909 | JPOST Repository
ProteomicsDataset14_SUDHL4 SAMHD1 KO 1h 8h Gemcitabine IMPRINTS
SUDHL4 SAMHD1 knockout cells were treated with 24uM gemcitabine for 1h and 8h (with 8h vehicle control), collected and subjected to CETSA heating, followed by cell lysis, isolation of soluble fraction and sample preparation for MS including digestion, desalting, TMT labeling, offline fractionation a...
ORGANISM(S): Homo Sapiens (human) 
2025-06-12 | PXD054912 | JPOST Repository
ProteomicsDataset13_SUDHL4 6h Gemcitabine ATRi IMPRINTS
SUDHL4 cells were treated with vehicle control, 24uM gemcitabine alone, DMSO, 6uM AZD6738 alone, or 24uM Gemcitabine with 6uM AZD6738 for 6h, collected and subjected to CETSA heating, followed by cell lysis, isolation of soluble fraction and sample preparation for MS including digestion, desalting, ...
ORGANISM(S): Homo Sapiens (human) 
2025-06-12 | PXD054911 | JPOST Repository
ProteomicsDataset08_SUDHL4 1h 8h low dose 2 Gemcitabine IMPRINTS
SUDHL4 cells were treated with 48nM gemcitabine for 1h and 8h (with 8h vehicle control), collected and subjected to CETSA heating, followed by cell lysis, isolation of soluble fraction and sample preparation for MS including digestion, desalting, TMT labeling, offline fractionation and pooling.
ORGANISM(S): Homo Sapiens (human) 
2025-06-12 | PXD055016 | JPOST Repository
ProteomicsDataset07_SUDHL4 1h 8h low dose 1 Gemcitabine IMPRINTS
SUDHL4 cells were treated with 480nM gemcitabine for 1h and 8h (with 8h vehicle control), collected and subjected to CETSA heating, followed by cell lysis, isolation of soluble fraction and sample preparation for MS including digestion, desalting, TMT labeling, offline fractionation and pooling.
ORGANISM(S): Homo Sapiens (human) 
2025-06-12 | PXD055015 | JPOST Repository
ProteomicsDataset10_SUDHL4 5h Gemcitabine ITDR
SUDHL4 cells were treated with increasing gemcitabine concentrations (and vehicle control) for 5h, collected and subjected to CETSA heating, followed by cell lysis, isolation of soluble fraction and sample preparation for MS including digestion, desalting, TMT labeling, offline fractionation and poo...
ORGANISM(S): Homo Sapiens (human) 
2025-06-12 | PXD054908 | JPOST Repository
Sort   by:  
 Page size